Survey on the Quality of the Top-Selling European and American Botanical Dietary Supplements Containing Boswellic Acids

Abstract

In consideration of the increasing popularity of frankincense and the widely published quality problems associated with botanical dietary supplements, a survey was conducted for the first time on the quality of frankincense containing botanical dietary supplements. Six US products representing 78 % of the units sold and 70 % of the market value, and 11 European products representing 30 % of the units sold and 40 % of the market value were tested for their boswellic acid composition profile, label compliance, and claimed health benefits. Special focus was also set on the statements made with regard to the frankincense applied.

Only five products out of seventeen disclosed all relevant information for the Boswellia extract, mentioning the species, the part of plant used, and the boswellic acid content. Whereas all products but one claimed to use Boswellia serrata, three products did not mention the resin as the part applied and 10 products did not declare the boswellic acid content. Apart from the different boswellic acid composition determined with a sensitive LC/MS method, 41 % of the products did not comply with the label declaration. Hence, one product from Italy did not contain any of the six characteristic boswellic acids (KBA, AKBA, αBA, βBA, AαBA, AβBA) at all and another US product contained only traces, suggesting the absence of frankincense or the use of Boswellia frereana instead of B. serrata. In another product, the ratios of the individual boswellic acids were different from B. serrata gum resin, indicating the use of another species such as Boswellia sacra or Boswellia carterii. Furthermore, two products revealed different boswellic acid contents from those declared on the label. Further, two products did not declare the use of manipulated Boswellia gum resin extract being enriched in acetyl-11-keto-boswellic acid content reaching up to 66 %. In addition, consumers could be misled by outdated literature or references to in vitro studies performed at dosages that can never be achieved in humans following oral administration.

In summary, this survey reveals that in spite of increased regulations on botanical dietary supplements, the problem of mislabeling still exists and needs to be addressed by the manufacturers, so that consumers get greater confidence in the botanical dietary supplements they use.

Key words

Boswellia - Burseraceae - boswellic acids - frankincense - botanical dietary supplements - herbal supplements

• References

• 1 Peregoy JA, Clarke TC, Jones LI, Stussman BJ, Nahin RL. Regional variation in use of complementary health approaches by U.S. adults. NCHS Data Brief 2014; 146: 1-8
• 2 World Health Organization. Traditional medicine. Fact Sheet N°134. Available at. http://www.who.int/mediacentre/factsheets/2003/fs134/en/ Accessed August 17, 2015
• 3 World Health Organization. National policy on traditional medicine and regulation on herbal medicine. Report of a WHO global survey. Geneva: World Health Organization; 2005
• 4 Global Industry Analyst, Inc.. Herbal supplements and remedies – global strategic business report. Available at. http://www.prweb.com/releases/herbal_supplements/herbal_remedies/pr.web9260421.htm Accessed March 14, 2016
• 5 Moraes CDF, Still DW, Lum MR, Hirsch AM. DNA-based authentication of botanicals and plant-derived dietary supplements: where have we been and where are we going?. Planta Med 2015; 81: 687-695
• 6 Fitzloff J, Yat P, Lu Z, Awang DVC, Arnason JT, van Breemen RB, Hall T, Blumenthal M, Fong HHS. Perspectives on the quality assurance of ginseng products in North America. In: Huh H, Choi KJ, Kim YC, editors Advances in Ginseng Research – Proceedings of the 7th International Symposium on Ginseng. Seoul, Korea: The Korean Society of Ginseng; 1998: 138-145
• 7 Monmaney T. Remedyʼs U.S. sales zoom, but quality control lags. The Los Angeles Times 1998; August 31: A1 – A10.
• 8 Schulz V, Hubner WD, Ploch M. Clinical trials with phyto-psychopharmacological agents. Phytomedicine 1997; 4: 379-387
• 9 Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011; 50: 349-369
• 10 Nieman DC, Shanely RA, Luo B, Dew D, Meaney MB, Sha W. A commercialized dietary supplement alleviates joint pain in community adults: a double-blind, placebo-controlled community trial. Nutr J 2013; 12: 154
• 11 Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: novel, specific, non-redox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992; 261: 1143-1146
• 12 Siemoneit U, Pergola C, Jazzar B, Northoff H, Skarke C, Jauch J, Werz O. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol 2009; 606: 246-254
• 13 Tausch L, Henkel A, Siemoneit U, Poeckel D, Kather N, Franke L, Hofmann B, Schneider G, Angioni C, Geisslinger G, Skarke C, Holtmeier W, Beckhaus T, Karas M, Jauch J, Werz O. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol 2009; 183: 3433-3442
• 14 Siemoneit U, Koeberle A, Rossi A, Dehm F, Verhoff M, Reckel S, Maier TJ, Jauch J, Northoff H, Bernhard F, Doetsch V, Sautebin L, Werz O. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br J Pharmacol 2011; 162: 147-162
• 15 Bannoa N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y, Nishimura R, Kimura Y, Suzuki T. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri . J Ethnopharmacol 2006; 107: 249-253
• 16 Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006; 1112: 255-262
• 17 Frutarom Select Line. AKBAmax. Available at. http://www.selectline.com/akbamax-p2950-en.html Accessed August 26, 2015
• 18 Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 1993; 38: 113-119
• 19 Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem 2006; 13: 3359-3369
• 20 Siemoneit U, Pergola C, Jazzar B, Northoff H, Skarke C, Jauch J, Werz O. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol 2009; 606: 246-254
• 21 Du Z, Liu Z, Ning Z, Liu Y, Song Z, Wang C, Lu A. Prospects of boswellic acids as potential pharmaceutics. Planta Med 2015; 81: 259-271
• 22 Shah SA, Rathod IS, Suhagia BN, Patel DA, Parmar VK, Shah BK, Vaishnavi VM. Estimation of boswellic acids from market formulations of Boswellia serrata extract and 11-keto-β-boswellic acid in human plasma by high-performance thin-layer chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 232-238
• 23 Shah SA, Rathod IS, Suhagia BN, Pandya SS, Parmar VK. A simple high-performance liquid chromatographic method for the estimation of boswellic acids from the market formulations containing Boswellia serrata extract. J Chromatogr Sci 2008; 46: 735-738
• 24 Ganzera M, Khan IA. A reversed phase high performance liquid chromatography method for the analysis of boswellic acids in Boswellia serrata . Planta Med 2001; 67: 778-780
• 25 Gerbeth K, Meins J, Kirste S, Momm F, Schubert-Zsilavecz M, Abdel-Tawab M. Determination of major boswellic acids in plasma by high-pressure liquid chromatography/mass spectrometry. J Pharm Biomed Anal 2011; 56: 998-1005